The effects of mesenchymal stem cells on the chemotherapy of colorectal cancer - 26/02/23
Abstract |
Colorectal cancer (CRC) has been the third commonest cancer in the world. The prognosis of patients with CRC is related to the molecular subtypes and gene mutations, which is prone to recurrence, metastasis, and drug resistance. Mesenchymal stem cells (MSCs) are a group of progenitor ones with the capabilities of self-renewal， multi-directional differentiation, and tissue re-population, which could be isolated from various kinds of tissues and be differentiated into diverse cell types. In recent years, MSCs are applied for mechanisms study of tissue repairing, graft-versus-host disease (GVHD) and autoimmune-related disease, and tumor development, with the advantages of anti‐inflammation, multi-lineage differentiation, and homing capability. Integrating the chemotherapy and MSCs therapy might provide a novel treatment approach for CRC patients. In this review, we summarize the current progress in the integrated treatment of integrating the MSCs and chemotherapy for CRC.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Combination of MSCs/modified MSCs and chemotherapeutic drugs in CRC forms a novel anti-cancer strategy.
Combination of MSCs/modified MSCs and chemotherapeutic drugs in CRC forms a novel anti-cancer strategy.ga1Le texte complet de cet article est disponible en PDF.
Highlights |
• | MSCs process tumor homing and immunomodulatory properties, providing new ideas for the anti-cancer therapies. |
• | MSCs and their exosomes have shown the therapeutic roles in CRC. |
• | Chemotherapeutic drugs and genes can be carried by MSCs to reduce the toxicity for CRC therapy. |
• | The combination of MSCs and chemotherapy can decrease the drug resistance. |
Abbreviations : ABC, AML, AMSCs, AOM, ASCs, BM, CAFs, CC-MSCs, CD, CFU-F, CR, CRC, CSCs, CXCR, DMEM, DOX, DSS, EMT, FMC, GCV, GBM, GDEPT, GEMP, GVHD, HMGB1, hP-MSCs, HSV-ttk, ICIs, iNOS, ITGA2, IL-6, ISCT, MHC, MSCs, mTOR, NPs, OVs, PAI-1, PDGFR, PEDF, P-gp, PLGA, CRAdNTR, PTBP1, PTX, ReoT3D, rASCs, RNL Bio, SIN, SPIO, SSc, TA-MSCs, TGFBR3, TME, TNF- TRAIL, TNTs, TP, α-MEM, VEGF, yCD, 5-FC
Keywords : Mesenchymal stem cells, Chemotherapy, Colorectal cancer
Plan
Vol 160
Article 114373- avril 2023 Retour au numéro
Article précédent
- Regulation of NcRNA-protein binding in diabetic foot
- Jiayu Zhang, Jing Zhang, Zhou Xu, Deju Zhang, Panpan Xia, Jitao Ling, Xiaoyi Tang, Xiao Liu, Rui Xuan, Meiying Zhang, Jianping Liu, Peng Yu
- Could a lipid oxidative biomarker be applied to improve risk stratification in the prevention of cardiovascular disease?
- Mariana Vieira de Mello Barros Pimentel, Adriana Bertolami, Lígia Prestes Fernandes, Lúcia Pereira Barroso, Inar Alves Castro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?